A new analysis provides further insight into factors affecting plaque stability and subsequent ischemic events

Ticagrelor, an antiplatelet medication from AstraZeneca commonly prescribed by cardiologists, gained FDA approval back in 2011. The author of a new investigative report, however, is raising several concerns about the data used to secure that approval.

Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.

According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation. 

An urgent device recall has been issued on Bravo CF, a line of pH capsules that are placed in the esophagus to aid in understanding the effects of acid reflux. Due to a dangerous manufacturing error, certain lots of the devices must be quarantined immediately.

The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.

The STS Risk Calculator App, available on both iOS and Android devices, gives users improved access to real-time risk assessments.

Kenneth Margulies, MD, will be the group's next president. These new terms all begin after the HFSA Annual Scientific Meeting in September.